The Role of Metronomic Chemotherapy in the Era of Cancer Immunotherapy: An Oncologist’s Perspective

S.Y. Tsao

doi:10.3747/co.26.4853

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Commentary

1 August 2019

The Role of Metronomic Chemotherapy in the Era of Cancer Immunotherapy: An Oncologist’s Perspective

Hong Kong Special Administrative Region Cancer Centre, Hong Kong SAR, China

Curr. Oncol.2019, 26(4), 422-424;https://doi.org/10.3747/co.26.4853

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Metronomic chemotherapy (MCTX) encompasses a set of chemotherapy (CTX) doses significantly below the conventional maximum tolerated dose (MTD) and delivered largely continually (without the prolonged drug-free breaks typical of MTD CTX). [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Lessons Learned from a Cancer Knowledge Translation Grants Program: Results of an Evaluation

Cannabis Use in Cancer: A Survey of the Current State at BC Cancer before Recreational Legalization in Canada